Sei Investments Co. Increases Stake in Healthpeak Properties, Inc. $DOC

Sei Investments Co. boosted its position in Healthpeak Properties, Inc. (NYSE:DOC) by 20.0% during the first quarter, HoldingsChannel reports. The fund owned 1,104,273 shares of the real estate investment trust’s stock after buying an additional 183,919 shares during the quarter. Sei Investments Co.’s holdings in Healthpeak Properties were worth $18,144,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in DOC. State Street Corp lifted its stake in Healthpeak Properties by 1.8% in the 3rd quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock worth $947,889,000 after purchasing an additional 895,460 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Healthpeak Properties by 8.6% in the 4th quarter. JPMorgan Chase & Co. now owns 30,674,812 shares of the real estate investment trust’s stock worth $493,251,000 after acquiring an additional 2,438,278 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Healthpeak Properties by 19.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock valued at $476,744,000 after acquiring an additional 4,776,056 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Healthpeak Properties by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 19,534,041 shares of the real estate investment trust’s stock valued at $312,959,000 after acquiring an additional 123,274 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of Healthpeak Properties by 9.9% during the 4th quarter. Invesco Ltd. now owns 18,298,776 shares of the real estate investment trust’s stock valued at $294,244,000 after acquiring an additional 1,648,012 shares during the last quarter. 93.57% of the stock is owned by hedge funds and other institutional investors.

Healthpeak Properties Price Performance

Shares of NYSE DOC opened at $22.45 on Thursday. Healthpeak Properties, Inc. has a 1 year low of $15.70 and a 1 year high of $22.95. The stock has a market capitalization of $15.47 billion, a P/E ratio of 70.14, a P/E/G ratio of 3.54 and a beta of 1.02. The company’s 50-day moving average is $20.92 and its 200 day moving average is $18.59. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.96 and a quick ratio of 2.96.

Healthpeak Properties (NYSE:DOC) last announced its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The business had revenue of $752.95 million during the quarter, compared to analyst estimates of $694.59 million. During the same quarter last year, the firm posted $0.46 earnings per share. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. On average, sell-side analysts expect that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current year.

Healthpeak Properties Dividend Announcement

The business also recently declared a monthly dividend, which will be paid on Friday, September 25th. Investors of record on Monday, September 14th will be paid a $0.1017 dividend. The ex-dividend date is Monday, September 14th. This represents a c) annualized dividend and a dividend yield of 5.4%. Healthpeak Properties’s dividend payout ratio is presently 381.25%.

Insider Activity at Healthpeak Properties

In other news, insider Scott R. Bohn sold 10,989 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the transaction, the insider directly owned 7,636 shares in the company, valued at $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.23% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DOC. Weiss Ratings raised shares of Healthpeak Properties from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. Morgan Stanley reaffirmed an “equal weight” rating and set a $22.00 price objective (up from $20.00) on shares of Healthpeak Properties in a report on Thursday, June 11th. Mizuho upped their target price on shares of Healthpeak Properties from $21.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Evercore cut Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 target price on the stock. in a research note on Monday, May 11th. Finally, Raymond James Financial began coverage on Healthpeak Properties in a research report on Wednesday, June 17th. They set a “market perform” rating on the stock. Four research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Healthpeak Properties currently has an average rating of “Hold” and an average target price of $20.62.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.